Comprehensive Complication Index in the Classification of Complications of Percutaneous Nephrolithotomy
NCT ID: NCT05351632
Last Updated: 2022-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
644 participants
OBSERVATIONAL
2022-05-01
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The CCI is essentially an index based on the CDC, but sums all postoperative complications by severity and scores them on an interval scale. It is scored from 0 (no complications) to 100 (patient's death) for each patient.
CCI in Urology Practice; Validated for Radical Cystectomy, Radical Prostatectomy, Radical Nephroureterectomy, Partial Nephrectomy.
In recent years, validation studies of this index have been carried out in endourological surgeries.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Complications in Patients Who Underwent LPN According to the CCI
NCT05823545
The Effect of Preoperative Culture Timing on Postoperative Outcomes of Retrograde Intrarenal Surgery
NCT06723327
Postoperative Kidney Functions in Geriatric Major Gynecologic-Oncologic Surgery
NCT05308810
Intraoperative NGAL Level in Geriatric Patients Undergoing Laparotomy
NCT05030727
Impact of Previous Open Renal Surgery on Percutaneous Nephrolithotomy Complications
NCT07097883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Using the free online tool www.assessurgery.com, the Comprehensive Complications Index (CCI) score for the total burden of complications will be calculated for each patient.
2. Each patient's most major complication will be determined and graded according to the Clavien-Dindo (CDC) classification (as described below).
Grade I: Any deviation from the normal postoperative course requiring only the following drugs: antiemetics, antipyretics, diuretics Grade II: Pharmacological therapy (with drugs not necessary for CDC I complications), blood transfusion, total parenteral nutrition Grade IIIa: Surgical, endoscopic or radiological intervention not under general anesthesia Grade IIIb: Surgical, endoscopic or radiological intervention under general anesthesia Grade IVa: single organ dysfunction requiring intensive care unit management Grade IVb: multiple organ dysfunction requiring intensive care unit management Grade V: Death
All the data obtained, CCI and CDC, will be compared among themselves in terms of reliability, demographic data obtained from the pre-operative file data, stone characteristics and data related to the operation will be compared, as well as their relationship with the length of hospital stay.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* To have given consent to participate in the study
* To be18 years of age or older
Exclusion Criteria
* Not to have given consent to participate in the study
* Not to have a medical indication for percutaneous kidney stone surgery
* To Have an orthopedic disorder that prevents him from undergoing percutaneous kidney stone surgery
* To have a hematological disorder that prevents percutaneous kidney stone surgery
* To have a malignancy that prevents percutaneous kidney stone surgery
* To have a serious cardiac and respiratory comorbidities that prevent percutaneous kidney stone surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zonguldak Bulent Ecevit University
OTHER
Ankara University
OTHER
Inonu University
OTHER
Istanbul University
OTHER
Acibadem University
OTHER
Eskisehir Osmangazi University
OTHER
Başakşehir Çam & Sakura City Hospital
OTHER_GOV
Koç University
OTHER
Izmir Metropolitan Municipality Esrefpasa Hospital
UNKNOWN
Alanya Alaaddin Keykubat University
OTHER
Cukurova University
OTHER
Ondokuz Mayıs University
OTHER
Dokuz Eylul University
OTHER
Samsun Education and Research Hospital
OTHER
Gazi University
OTHER
Hacettepe University
OTHER
Abant Izzet Baysal University
OTHER
Ankara Training and Research Hospital
OTHER
Hitit University
OTHER
Baskent University
OTHER
Marmara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yiloren Tanidir
Associ.Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reha GİRGİN, Assist.Prof.
Role: STUDY_DIRECTOR
Zonguldak Bulent Ecevit University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zonguldak Bülent Ecevit University, school of medicine
Zonguldak, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022/06-7
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.